All In Biotech

Drug Trial Radar · NCT02469090

Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy, Safety and Tolerability of APL-130277 in Levodopa Responsive Patients With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Last checked: Nov 19, 2026Latest source record: Jul 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 141 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

141

Actual

Start

Jun 18, 2015

Primary completion

Dec 11, 2017

Study completion Dec 11, 2017

Sponsor

Lead sponsor
Sumitomo Pharma America, Inc.Industry
Sponsor type
Industry
First posted
Jun 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 12-week, prospective, multi-center, randomized, double-blind, placebo controlled, Phase 3 study in L-Dopa responsive PD patients with motor fluctuations ("OFF" episodes), designed to determine the efficacy, safety and tolerability of APL-130277.

Conditions

  • Parkinson Disease, Off Episodes

Interventions

  • APL-130277Drug

    Use to treat up to 5 "OFF" episodes per day

  • PlaceboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Pre-Dose to 30 Minutes Post-Dose in The Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Motor Examination (MDS-UPDRS Part III) Score at Maintenance Visit 4 (MV4) - Week 12Time frame: At t=0 (just prior to dosing) and t=30 minutes at MV4 (Week 12 of the Maintenance Treatment Phase).

Locations

33 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama, Birmingham

    Birmingham, Alabama

  • Muhammed Ali Parkinson and Movement Disorder CenterBarrow Neurological

    Phoenix, Arizona

  • Movement Disorders Center of Arizona

    Scottsdale, Arizona

  • Mayo Clinic Arizona

    Scottsdale, Arizona

  • The Parkinson's and Movement Disorder Institute

    Fountain Valley, California

  • UC Irvine Health Gottschalk Medical Plaza

    Irvine, California

  • Keck Medical Center at USC

    Los Angeles, California

  • The Research Center of Southern California

    Oceanside, California

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia

  • Parkinsons Disease and Movement Disorders Center

    Boca Raton, Florida

  • University of Miami, Miller School of Medicine

    Miami, Florida

  • Parkinson's Disease Treatment Center of Southwest Florida

    Port Charlotte, Florida

  • USF Parkinson's Disease and Movement Disorder Center

    Tampa, Florida

  • Emory University Department of Neurology

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Rush University Medical Center

    Chicago, Illinois

  • Central DuPage Hospital - Neurodegenerative Clinic - Movement Disorders Center

    Winfield, Illinois

  • Kansas University Medical Center - Department of Neurology

    Kansas City, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Johns Hopkins University

    Baltimore, Maryland

  • QUEST Research Institute

    Farmington Hills, Michigan

  • Northern Michigan Neurology

    Traverse City, Michigan

  • Henry Ford Hospital

    West Bloomfield, Michigan

  • Columbia University Medical Center - Neurological Institute, Movement Disorders

    New York, New York

  • Raleigh Neurology Associates, P.A.

    Raleigh, North Carolina

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • University of Cincinnati

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • The Movement Disorder Clinic of Oklahoma

    Tulsa, Oklahoma

  • Jefferson University Hospital Philadelphia

    Philadelphia, Pennsylvania

  • University of Virginia, Adult Neurology

    Charlottesville, Virginia

  • Evergreen Health

    Kirkland, Washington

  • UHN Toronto Western Hospital

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.